CONMED Beats, Earnings Rise 5.3% - Analyst Blog


Shutterstock photo

CONMED Corporation ( CNMD ) posted adjusted earnings per share of 49 cents for the 2014-first quarter, up 8.9% from 45 cents in the same quarter of 2013 as well as the Zacks Consensus Estimate by a couple of cents. Net earnings improved 5.3% to $13.5 million from $12.9 million in the same quarter of 2013.

Revenues in the quarter dipped 2.7% (2.1% on a constant currency basis) to $181.9 million. The decrease was attributable to weaker sales of capital products. International sales in the quarter were $94.6 million, accounting for 52.0% of total sales.

Revenues from orthopedic surgery business edged up 0.9% (or 1.9% in constant currency) to $105.9 million. Revenues from general surgery were down 4.9% (or 4.6% in constant currency) to $63.5 million. Revenues from surgical visualization slipped 17.8% (or 17.1% in constant currency) to $12.5 million.


Adjusted operating earnings in the quarter rose 11.1% to $21.5 million. Adjusted margin in the quarter rose 150 basis points (bps) to 11.8% from 10.3% in the first quarter of 2013.

Adjusted EBITDA scaled up 4.0% to $33.4 million in the quarter. Adjusted EBITDA margin rose 120 bps to 18.3% from 17.1% in the first quarter of 2013.

Financial Position

CONMED exited the year with cash and cash equivalents of $56.3 million as of Mar 31, 2014, up 3.4% from $54.4 million as of Dec 31, 2013. Long-term debt (inclusive of current portion) increased 12.5% to $242.6 million from $215.6 million as of Dec 31, 2013. Consequently, long-term-debt-to-capitalization ratio rose 270 bps to 28.9% from 26.2% as of Dec 31, 2013.

In the quarter, CONMED's operating cash flow increased more than threefold to $17.0 million versus $5.5 million in the prior-year quarter, mainly due to lower accounts receivable. Capital expenditures fell 1.6% to $4.1 million in the quarter.


For the 2014-second quarter, CONMED expects revenues in the band of $190-$195 million. Meanwhile, adjusted earnings per share are expected between 44 and 48 cents for the quarter.

For full year 2014, CONMED reiterated its revenues guidance in the range of $770 to $780 million, reflecting a 1-2% rise from 2013 based on continued single use products sales growth and improved capital products sales. It compared with the Zacks Consensus Estimate of $776 million.

Adjusted earnings per share continued to be anticipated between $1.90 and $2.00 compared with the Zacks Consensus Estimate of $1.94. The expected earnings per share implies a 5-10.5% rise from 2013.

Zacks Rank

Currently, CONMED carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical/dental supplies industry include Align Technology Inc. ( ALGN ), Cardinal Health, Inc. ( CAH ), and The Cooper Companies Inc. ( COO ). All these stocks carry a Zacks Rank #2 (Buy).

ALIGN TECH INC (ALGN): Free Stock Analysis Report

CARDINAL HEALTH (CAH): Free Stock Analysis Report

CONMED CORP (CNMD): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Earnings , Stocks
More Headlines for: ALGN , CAH , CNMD

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by